Increased gamma-aminobutyric acid (GABA), homocarnosine and beta-alanine in cerebrospinal fluid of patients treated with gamma-vinyl GABA (4-amino-hex-5-enoic acid).
D000612:4-Aminobutyrate Transaminase / Q000037:antagonists & inhibitors; D000328:Adult; D000368:Aged; D000409:Alanine / Q000134:cerebrospinal fluid*; D000614:Aminocaproates / Q000009:adverse effects* / Q000627:therapeutic use; D002336:Carnosine / Q000031:analogs & derivatives / Q000134:cerebrospinal fluid*; D002852:Chromatography, Ion Exchange; D004151:Dipeptides / Q000134:cerebrospinal fluid*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013050:Spectrometry, Fluorescence; D020888:Vigabatrin; D015091:beta-Alanine / Q000134:cerebrospinal fluid*; D005680:gamma-Aminobutyric Acid / Q000134:cerebrospinal fluid*
D000614:Aminocaproates; D004151:Dipeptides; D015091:beta-Alanine; C005038:homocarnosine; D005680:gamma-Aminobutyric Acid; D002336:Carnosine; D000612:4-Aminobutyrate Transaminase; D020888:Vigabatrin; D000409:Alanine